Most patients with Alzheimer's disease and Alzheimer's Disease Related Dementias (ADRD) experience the gradual onset and progression of cognitive symptoms, leading to decline over years or decades. However, in a small subset of patients, symptoms begin rapidly, leading to dementia within one year and complete incapacitation within two years of symptom onset. A new study at Mayo Clinic aims to determine why patients with Alzheimer’s disease and ADRD develop this rapidly progressive dementia (RPD).

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) and simultaneously published in JACC. The overall rate of cardiovascular death or worsening heart failure, the trial’s primary endpoint, was higher in the 60% of study participants who also had chronic kidney disease. However, tirzepatide reduced the risk of the primary endpoint to a similar degree in patients with and without kidney disease.

Researchers at The University of Texas at Dallas have invented a new, inexpensive method for fabricating artificial muscles for potential use in robots, in comfort-adjusting jackets that become more thermally insulating as the surrounding air becomes colder, and as mechanical energy harvesters.

Neurologists at The University of Texas Health Science Center at San Antonio are among the nation's first to use new technology to treat patients with movement disorders with deep brain stimulation that automatically adapts as symptoms change.

Researchers from the GenX Exposure Study have detected PFAS (per- and polyfluoroalkyl substances) associated with a nearby fluorochemical plant in the household dust of homes located in Cumberland and Bladen counties, North Carolina. Homes closer to the plant had higher concentrations of those specific PFAS than homes located farther away.

Using recent advances in AI-based modeling, researchers from UC Berkeley and UC San Francisco developed a neuroprosthesis that synthesizes brain signals into audible speech in near-real time. The advance enables a more naturalistic speech pattern for people unable to talk because of paralysis.